Platelet-Derived Growth Factor as a Therapeutic Target for Systemic Autoimmune Diseases
Some systemic rheumatic diseases and disorders, especially fibrotic and vascular disorders, are often refractory to corticosteroid therapy. Recently, ever accumulating evidence suggests that platelet-derived growth factor (PDGF) is involved in those refractory diseases. Imatinib mesylate inhibits th...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
AboutScience Srl
2007-01-01
|
| Series: | Drug Target Insights |
| Online Access: | https://doi.org/10.1177/117739280700200006 |